Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).
Researchers at Vanderbilt University Medical Center have isolated human monoclonal antibodies against influenza B, a significant public health threat that disproportionately affects children, the elderly and other immunocompromised individuals.
Pediatric Impact of COVID-19 and Other Respiratory Infections Clinical Prediction Tool for Prioritizing Respiratory Syncytial Virus Prevention Products for High-Risk Infants During Current Limited Availability of Nirsevimab in the United States
Patients with fibromyalgia and irritable bowel syndrome (IBS) who take multiple medications are more likely to develop severe drug intolerance than healthy patients, UT Southwestern Medical Center researchers reported. Their findings, published in The Journal of Allergy and Clinical Immunology: In Practice, could help health professionals prescribe drugs for patients and identify treatment plans for multiple drug intolerance syndrome (MDIS).
By completely or even partially depleting a protein called midnolin in B cells, UT Southwestern Medical Center researchers suppressed leukemia and lymphoma in a mouse model genetically prone to these cancers. Their findings, reported in the Journal of Experimental Medicine, could lead to new treatments for these diseases that avoid the serious side effects of current therapies.
Over 150 researchers from across the University of Utah gathered to form new connections and share groundbreaking research on topics from antibiotic resistance to autoimmune diseases.
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.
A study led by Yale scientists, published April 25 in the journal Science Immunology, investigated the potential causes associated with T cell exclusion using a genome-wide screen of more than 1,000 human proteins.
The American Association of Immunologists (AAI) today announced its publishing partnership with Oxford University Press (OUP). OUP will publish the AAI journals, The Journal of Immunology (The JI) and ImmunoHorizons (IH), beginning in 2025.
Today the American Association of Immunologists (AAI), one of the world’s largest organizations of immunologists and scientists in related disciplines, is proud to announce the launch of its new brand identity.
Researchers say a machine learning tool can identify many patients with rare, undiagnosed diseases years earlier, potentially improving outcomes and reducing cost and morbidity. The findings, led by researchers at UCLA Health, are described in Science Translational Medicine.
A groundbreaking study has recognized the cGAS-STING signaling pathway as a formidable ally in the immune system's battle against cancer. This pivotal discovery may pave the way for innovative immunotherapies capable of amplifying the body's inherent defenses to detect and eradicate cancer cells, signifying a substantial advance towards more potent cancer treatments.
This method is a major leap forward for scientists investigating how proteins do their jobs in the immune system. “This method basically creates an entire new kind of world of experiments that people can do..."
Alexander Gow, Ph.D., professor and associate director of the Center for Molecular Medicine and Genetics and professor of pediatrics and neurology at the Wayne State University School of Medicine, received an award from the National Multiple Sclerosis Society for a study into the causes of multiple sclerosis.
The grant will explore the early roots of Multiple Sclerosis (MS) in patients that Gow believes may begin years — perhaps even decades — before symptoms become apparent.
Miriam Merad, MD, PhD, a world-renowned immunologist, has been appointed Dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. The appointment reaffirms Icahn Mount Sinai’s commitment to pioneering medical progress and catalyzing the rapid advancement of research innovation. Dr. Merad, the Mount Sinai Professor in Cancer Immunology, will also continue to serve as the founding Chair of the Department of Immunology and Immunotherapy, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and Director of the Human Immune Monitoring Center.
As Dean, Dr. Merad aims to elevate early clinical trials at Icahn Mount Sinai, streamline the clinical trial process, cultivate a culture of mechanistic clinical trials throughout the campus, and forge stronger partnerships with the pharmaceutical and biotech sectors.
May is Asthma and Allergy Awareness Month – the ideal time to get the word out on the different types of asthma, as well as the different triggers and treatments.